C
Christopher F. Mojcik
Researcher at Alexion Pharmaceuticals
Publications - 14
Citations - 3484
Christopher F. Mojcik is an academic researcher from Alexion Pharmaceuticals. The author has contributed to research in topics: Complement inhibitor & Paroxysmal nocturnal hemoglobinuria. The author has an hindex of 10, co-authored 14 publications receiving 3196 citations. Previous affiliations of Christopher F. Mojcik include Leeds Teaching Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Journal ArticleDOI
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
TL;DR: The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Journal ArticleDOI
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Claire Hall,Judith C. W. Marsh,Modupe O. Elebute,Michael P Bombara,Beth E. Petro,Matthew J. Cullen,Stephen J. Richards,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother +10 more
TL;DR: This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.
Journal ArticleDOI
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
Anita Hill,Peter Hillmen,Peter Hillmen,Stephen J. Richards,Stephen J. Richards,Dupe Elebute,Dupe Elebute,Judith C. Marsh,Judith C. Marsh,Jason Yongsheng Chan,Jason Yongsheng Chan,Christopher F. Mojcik,Christopher F. Mojcik,Russell P. Rother,Russell P. Rother +14 more
TL;DR: Eculizumab, administered at 900 mg every 12 to 14 days, was sufficient to completely and consistently block complement activity in all patients, and the close relationship between sustained terminal complement inhibition, hemolysis, and symptoms was demonstrated.
Journal ArticleDOI
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Edward D. Verrier,Stanton K. Shernan,Kenneth M. Taylor,Frans Van de Werf,Mark F. Newman,John C. Chen,Michel Carrier,Axel Haverich,Kevin J. Malloy,Peter X. Adams,Thomas G. Todaro,Christopher F. Mojcik,Scott A. Rollins,Jerrold H. Levy +13 more
TL;DR: Compared with placebo, pexelizumab was not associated with a significant reduction in the risk of the composite end point of death or MI in 2746 patients who had undergone CABG surgery only but was related with a statistically significant risk reduction 30 days after the procedure among all 3099 patients undergoing CabG with or without valve surgery.